mo . This patient remains in continuous complete remission off of therapy. For all three patients, EBVtransformed B lymphocyte lines were established from PBL (4) . T cell lines were generated by coculture of patient's PBL with an irradiated (10,000 rad) mixture of autologous tumor and EBVtransformed B lymphoblasts (5 :1). The CTL-A2 line was derived by coculture of the PBL from a normal donor (HLA-A3; B7, w38; DR6) with the irradiated B cell line JY (HLA-A2 ; B7 ; DR4,6) (5, 6) . Tumor and EBVtransformed cell lines were maintained in RPMI 1640 supplemented with 10% calf serum. T cell lines were maintained in RPMI 1640 supplemented with 10% FCS and T cell growth factors (7) and were stimulated weekly with the irradiated mixture designated above. Cells were cloned by limiting dilution (8) .
5'Cr-release Assays . Assays were carried out for 4 h as previously described (9) . Antibodies were added at the beginning of the assay and were present throughout.
Monoclonal Antibodies . The following mAbs specific for the indicated molecules were used for cell surface staining and/or inhibition of cytolysis: Leu-1/anti-CD1, OKT4/anti-CD4, OKT8/anti-CD8; PA2.6/anti-HLA class I (10) ; OKT3/anti-CD3; TS1.16/anti-HLA class II (11) ; TS1.18/anti-LFA-1 (CDw18) (9); WT31/antiTCRa/ß (12); TCR6I/anti TCR--y/S (13). The antiidiotype, A, A, and K mAbs were prepared and characterized as described (14) (15) (16) .
Results and Discussion
Antitumor CTL were derived by in vitro coculture of the PBL from three separate patients with an irradiated mixture of their autologous Burkitt's lymphoma tumor cells plus an autologous B lymphoblastoid cell line derived from EBVtransformed PBL. Cell lines generated under these conditions were stable for at least 6 mo in continuous culture. Antitumor CTL could not be generated by culturing PBL from two of these patients with only their autologous tumor cell lines (SUP-1112, SUP-B17) without the EBVtransformed lines. This may reflect the lack of expression of the lymphocyte function-associated antigen 1 (LFA-1) on the SUP-1112 and SUP-B17 tumor cells (4) . The SUP-118 cell line expresses normal levels of LEA-1 (4) .
After the cells were in culture for 6 wk their specificity was ascertained with a panel of 40 target cells ( Fig. 1, with 16 representative lines) . Cell lines were gener-FIGURE .1 .
Specificity of cytolysis by antitumor CTL. The antitumor CTL from three patients were tested for cytolytic activity in a standard ated from each patient on at least six separate occasions, and the specificity oflysis by each line was similar to the results shown here . The CTL lines generated from patients 1 and 3 lysed only their autologous tumor cell lines and not the autologous EBV lines. The CTL line generated from patient 2 lysed not only the autologous tumor cell line SUP-118 but also all targets expressing HLA-DR1 (Pally, LCL-158, SUP-118 shown) . Treatment of this heterogeneous CTL line with mAb to CD4 and complement showed that only CD4+ CTL lysed the HLA-DR1 + targets whereas CD4 -CTL specifically lysed the autologous SUP-1117 tumor (data not shown) .
To localize the epitopes of the tumor-specific antigens recognized by these CTL, we tested mAb to idiotype, j,, and X or K for inhibition of cytolysis. The isotype of the Ig expressed by the SUP-118 and SUP-1112 cell lines is U/ic ; that of the SUP-1317 cell line is A/X Our specificity controls were alloreactive CTL derived from normal donors and specific for HLA-A2 (5, 6) . In all three cases, mAbs to Ig specifically inhibited tumor directed cytolysis (Fig. 2) . Lysis of SUP-1112 cells by the autologous CTL line was specifically inhibited by anti-SUP-1112 idiotype and anti-,u. Similarly, lysis of SUP-118 cells by the autologous antitumor CTL line was inhibited by anti-SUP-118 idiotype and anti-,u . Finally, lysis of SUP-1317 cells was inhibited by anti-X and andidiotype, but not by anti-,u. In each case, lysis was inhibited only by the mAb to the specific tumor idiotype and not by mAb to either of the other two tumor idiotypes. Thus, Ig determinants can serve as target antigens in an autologous system . 
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FIGURE 2. mAbs to Ig inhibit cytolysis by tumor-specific CTL. Lysis of tumor cells by the autologous antitumor CTL line or the HLA-A2-specific CTL CTL-A2 was tested using an E/T ratio of 1 :1 . The targets were SUP-1112, SUP-118, and SUP-1117 for patients 1, 2, and 3, respectively. Similar inhibition was observed at E/T ratios of 2:1 and 5 :1 . These E/T ratios were chosen because they fall on the linear portion of thelysis curve. Purified antibodies were added at a final concentration of 25 pg/ml to 5iCr-labeled targets for 20 min at room temperature before the addition of CTL. Anti-ic chain was used for SUP-118 and SUP-1312 and anti chain was used for SUP-1117 . Results shown are from one of five similar experiments. In experiments not shown, mAb were titrated from 50 pg/ml down to 1 jLg/ml. Inhibition was observed at all concentrations and the percent inhibition decreased proportionately with the concentration of mAb.
Since cytotoxicity is tumor cell specific, the target determinants are presumably the Ig idiotype .
To confirm that Ig was the target antigen and to establish the phenotype of these tumor specific CTL, we cloned CTL by limiting dilution . Clones were obtained only from patient 3. Clones that lysed the autologous tumor cell line SUP-1317 were expanded . Four T cell clones lysed the autologous tumor cell line but not the autologous EBV B cell line or any of 40 other target cells tested, including SUP-138, SUP-B12, and five other Burkitt's cell lines (data not shown) . Lysis was inhibited by mAb to A, but not by mAbs to u or the idiotype (Fig . 3) . Thus, this particular CTL clone may recognize an idiotypic determinant associated with the A light chain but distinct from the epitope recognized by the antiidiotypic mAb. The polyclonal CTL line from which this CTL was cloned contained cells which could be inhibited by mAb to A and idiotype (Fig. 2) .
To identify other molecules involved in the lysis of the SUP-1317 tumor cells, we tested mAb to various cell surface molecules for inhibition of cytolysis (Fig . 3) . The results for the heterogeneous CTL cultures and all four CTL clones were similar. Lysis of SUP-1317 by clone 18 was inhibited only by the mAb to CD3 (OKT3) and a mAb to the a subunit of LFA-1 (TSl/18) ; mAbs specific for CD4 (OKT4), CD8 (OKT8), MHC class I (PA2 .6), and MHC class II (TSl/16) antigens had no inhibitory effect .
In contrast, lysis of both SUP-1317 and JY cells by the HLA-A2-specific CTL line CTL-A2 (5, 6) was inhibited by mAbs to HLA-class I, CD3, CD8, and LFA-1, as has been shown previously for CTL that are HLA class I restricted and express CD3 and CD8 (5, 6, 9) .
Since mAbs to CD4, CD8, or MHC molecules did not affect lysis by the tumorspecific CTL clones, we examined the cell surface phenotype of the clones and the heterogeneous CTL line from which they were derived (Fig. 4) . All four clones (represented by clone 18, panel A) and the parental anti-SUP-1317 T cell line were strongly positive for CD3 expression . Approximately two-thirds of the parental T cell line (panel B) expressed the CD8 molecule, but no 101314-expressing cells were detected . None of the four clones expressed either CD4 or CD8 molecules. Since the lack of expression of both CD4 and CD8 molecules has been associated with expression of the TCRy/S (15-17), the molecular nature of the TCR on these cells was investigated with two mAbs to the TCR (Fig. 4 E-H) . WT31, a mAb to a framework determinant on the TCRa/(3-CD3 complex (12) reacted strongly with the Jurkat cell line (Fig. 4 H) . TCR61 is a mAb to the TCR6 chain that was produced by immunization with the purified TCRy/6 complex from the leukemic cell line PEER (13) . Most CTL in the parental anti-SUP-1317 cell line were stained with the TCR61 mAb, while a minor population was positive for WT31 (Fig . 4 F) . A representative clone (clone 18) was positive for TCR61; no binding of WT31 was detected (Fig.  4 E) . Since, as far as is known, the TCR 6 chain is invariably expressed as part of (18), we assume that these cells also express the TCR y chain .
Although TCR-6 genes are rearranged and expressed early in thymic ontogeny (19) (20) (21) (22) , there are very few cells with TCRy/6 heterodimers detectable in the thymus or periphery at birth . In human adults, only 3-10% of peripheral T cells express a TCRy/b (23) (24) (25) . Many IL-2-dependent T cell lines and clones that express TCR-y/b exhibit cytotoxicity against a broad panel of tumor targets (16, 17, 27) . Recognition and cytotoxicity are neither restricted by nor directed against MHC antigens, so that it is possible that T cells expressing TCRy/6 mediate MHC-unrestricted cytotoxicity. However, it is unclear whether such nonspecific cytotoxicity is a result of in vitro culture or reflects the in vivo activity of these cells .
CTL lines with a similar specificity for autologous tumor targets were established from these patients on >20 separate occasions over the past 2 yr. During this period, patient 3 was on continuation chemotherapy and the percentage of CD3+,CD4-, CD8-cells in his peripheral blood ranged from 15 to 50% (data not shown) . We cannot establish whether these CD4-,CD8-,y/b+ cells arose as a result of host factors, such as malignancy or chemotherapy, or because ofthe stimulatory antigens present on the autologous tumor. Nonetheless, our findings suggest a physiologic role for T cells with TCR-y/b in MHC-unrestricted autologous tumor cell recognition and raise the intriguing possibility that some but not all (16, 28, The effectiveness of such CTL is in part dependent on recognition oftumor specific antigens. Among the best characterized tumor-specific antigens are the unique or idiotypic determinants on the Ig of B cell lymphomas . Here we describe the generation and properties of human CTL specific for the idiotype on autologous B cell tumors. These cells are CD3 +,CD4-,CD8-and express the b chain of the TCR . Such cells may prove useful in tumor-specific adoptive therapy.
